307 related articles for article (PubMed ID: 12385818)
1. Rotenone destroys dopaminergic neurons and induces parkinsonian symptoms in rats.
Alam M; Schmidt WJ
Behav Brain Res; 2002 Oct; 136(1):317-24. PubMed ID: 12385818
[TBL] [Abstract][Full Text] [Related]
2. Acute intranigral infusion of rotenone in rats causes progressive biochemical lesions in the striatum similar to Parkinson's disease.
Saravanan KS; Sindhu KM; Mohanakumar KP
Brain Res; 2005 Jul; 1049(2):147-55. PubMed ID: 15936733
[TBL] [Abstract][Full Text] [Related]
3. L-deprenyl protects against rotenone-induced, oxidative stress-mediated dopaminergic neurodegeneration in rats.
Saravanan KS; Sindhu KM; Senthilkumar KS; Mohanakumar KP
Neurochem Int; 2006 Jul; 49(1):28-40. PubMed ID: 16490285
[TBL] [Abstract][Full Text] [Related]
4. Progressive loss of dopaminergic neurons induced by unilateral rotenone infusion into the medial forebrain bundle.
Norazit A; Meedeniya AC; Nguyen MN; Mackay-Sim A
Brain Res; 2010 Nov; 1360():119-29. PubMed ID: 20807515
[TBL] [Abstract][Full Text] [Related]
5. The neurobehavioral changes induced by bilateral rotenone lesion in medial forebrain bundle of rats are reversed by L-DOPA.
Alam M; Mayerhofer A; Schmidt WJ
Behav Brain Res; 2004 May; 151(1-2):117-24. PubMed ID: 15084427
[TBL] [Abstract][Full Text] [Related]
6. Behavioral alterations in rotenone model of Parkinson's disease: attenuation by co-treatment of centrophenoxine.
Nehru B; Verma R; Khanna P; Sharma SK
Brain Res; 2008 Mar; 1201():122-7. PubMed ID: 18308296
[TBL] [Abstract][Full Text] [Related]
7. Drp1, a potential therapeutic target for Parkinson's disease, is involved in olfactory bulb pathological alteration in the Rotenone-induced rat model.
Zhang X; Huang W; Shao Q; Yang Y; Xu Z; Chen J; Zhang X; Ge X
Toxicol Lett; 2020 Jun; 325():1-13. PubMed ID: 32088201
[TBL] [Abstract][Full Text] [Related]
8. Controversies on new animal models of Parkinson's disease pro and con: the rotenone model of Parkinson's disease (PD).
Schmidt WJ; Alam M
J Neural Transm Suppl; 2006; (70):273-6. PubMed ID: 17017541
[TBL] [Abstract][Full Text] [Related]
9. L-DOPA reverses the hypokinetic behaviour and rigidity in rotenone-treated rats.
Alam M; Schmidt WJ
Behav Brain Res; 2004 Aug; 153(2):439-46. PubMed ID: 15265640
[TBL] [Abstract][Full Text] [Related]
10. Forced exercise activates the NrF2 pathway in the striatum and ameliorates motor and behavioral manifestations of Parkinson's disease in rotenone-treated rats.
Monir DM; Mahmoud ME; Ahmed OG; Rehan IF; Abdelrahman A
Behav Brain Funct; 2020 Nov; 16(1):9. PubMed ID: 33158454
[TBL] [Abstract][Full Text] [Related]
11. Behavioral and immunohistochemical effects of chronic intravenous and subcutaneous infusions of varying doses of rotenone.
Fleming SM; Zhu C; Fernagut PO; Mehta A; DiCarlo CD; Seaman RL; Chesselet MF
Exp Neurol; 2004 Jun; 187(2):418-29. PubMed ID: 15144868
[TBL] [Abstract][Full Text] [Related]
12. Neuroprotective effects of indole-3-carbinol on the rotenone rat model of Parkinson's disease: Impact of the SIRT1-AMPK signaling pathway.
Mohamad KA; El-Naga RN; Wahdan SA
Toxicol Appl Pharmacol; 2022 Jan; 435():115853. PubMed ID: 34973289
[TBL] [Abstract][Full Text] [Related]
13. Chronic low-dose melatonin treatment maintains nigrostriatal integrity in an intrastriatal rotenone model of Parkinson's disease.
Carriere CH; Kang NH; Niles LP
Brain Res; 2016 Feb; 1633():115-125. PubMed ID: 26740407
[TBL] [Abstract][Full Text] [Related]
14. Chronic systemic pesticide exposure reproduces features of Parkinson's disease.
Betarbet R; Sherer TB; MacKenzie G; Garcia-Osuna M; Panov AV; Greenamyre JT
Nat Neurosci; 2000 Dec; 3(12):1301-6. PubMed ID: 11100151
[TBL] [Abstract][Full Text] [Related]
15. Rotenone induces oxidative stress and dopaminergic neuron damage in organotypic substantia nigra cultures.
Testa CM; Sherer TB; Greenamyre JT
Brain Res Mol Brain Res; 2005 Mar; 134(1):109-18. PubMed ID: 15790535
[TBL] [Abstract][Full Text] [Related]
16. Enhanced sensitivity of dopaminergic neurons to rotenone-induced toxicity with aging.
Phinney AL; Andringa G; Bol JG; Wolters ECh; van Muiswinkel FL; van Dam AM; Drukarch B
Parkinsonism Relat Disord; 2006 May; 12(4):228-38. PubMed ID: 16488175
[TBL] [Abstract][Full Text] [Related]
17. Neonatal systemic exposure to lipopolysaccharide enhances susceptibility of nigrostriatal dopaminergic neurons to rotenone neurotoxicity in later life.
Cai Z; Fan LW; Kaizaki A; Tien LT; Ma T; Pang Y; Lin S; Lin RC; Simpson KL
Dev Neurosci; 2013; 35(2-3):155-71. PubMed ID: 23446007
[TBL] [Abstract][Full Text] [Related]
18. Characterisation of a novel model of Parkinson's disease by intra-striatal infusion of the pesticide rotenone.
Mulcahy P; Walsh S; Paucard A; Rea K; Dowd E
Neuroscience; 2011 May; 181():234-42. PubMed ID: 21277943
[TBL] [Abstract][Full Text] [Related]
19. D-beta-hydroxybutyrate protects dopaminergic SH-SY5Y cells in a rotenone model of Parkinson's disease.
Imamura K; Takeshima T; Kashiwaya Y; Nakaso K; Nakashima K
J Neurosci Res; 2006 Nov; 84(6):1376-84. PubMed ID: 16917840
[TBL] [Abstract][Full Text] [Related]
20. The rotenone-induced rat model of Parkinson's disease: behavioral and electrophysiological findings.
von Wrangel C; Schwabe K; John N; Krauss JK; Alam M
Behav Brain Res; 2015 Feb; 279():52-61. PubMed ID: 25446762
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
